Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adaptive Biotechnologies Corp (NQ: ADPT )

7.310 -0.060 (-0.81%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 723,418
Open 7.390
Bid (Size) 7.100 (5)
Ask (Size) 7.590 (1)
Prev. Close 7.370
Today's Range 7.190 - 7.510
52wk Range 5.955 - 13.21
Shares Outstanding 144,311,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cathie Wood Goes Bargain-Hunting: 3 Stocks She Just Bought
There are always stocks to buy if you're Ark Invest's ace stock picker. 
Via The Motley Fool
Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer
From Adaptive Biotechnologies
Via GlobeNewswire

Performance

YTD
-6.28%
-6.28%
1 Month
+2.67%
+2.67%
3 Month
-8.63%
-8.63%
6 Month
-11.29%
-11.29%
1 Year
-2.53%
-2.53%

More News

Read More
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Via The Motley Fool
Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
From Adaptive Biotechnologies
Via GlobeNewswire
3 Personalized Medicine Stocks to Buy for Long-Time Returns
Via InvestorPlace
Adaptive Biotechnologies's Return On Capital Employed Insights
Via Benzinga
Adaptive Biotechnologies: Q1 Earnings Insights
Via Benzinga
What To Know About Piper Sandler's Upgrade of Adaptive Biotechnologies
Via Benzinga
Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Reports First Quarter 2023 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Participate in the BofA Securities 2023 Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023
From Adaptive Biotechnologies
Via GlobeNewswire
Luminar Technologies, EHang Holdings And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Adaptive Biotechnologies to Participate in the 43rd Annual Cowen Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
Trade Desk, Roblox, Herbalife And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
Earnings Scheduled For February 14, 2023
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 14, 2023
From Adaptive Biotechnologies
Via GlobeNewswire
Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Why Venus Concept Shares Are Trading Higher By Over 63%? Here Are 58 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.